Abstract:BackgroundNitrous oxide (N 2 O), used medically for its analgesic and anxiolytic properties, has emerged as a common recreational substance, leading to a rise in chronic toxicity cases. N 2 O abuse induces peripheral neurological damage with a spectrum of clinical presentations, ranging from mild sensory disturbances to severe motor deficits. Neurological complications from N 2 O include axonal and demyelinating neuropathies, leading to diagnostic and prognostic challenges. The pathophysiology of N 2 O toxicity is linked to functional inactivation of vitamin B12, resulting in biochemical and electrophysiological alterations. This study aims to enhance understanding of N 2 O pathophysiology by examining metabolic changes in consumers with axonal and demyelinating patterns.MethodsThis study included 35 patients with recent N 2 O abuse (last declarative consumption within the past week) who were treated at Lille University Hospital between March 2020 and April 2023 and underwent electromyography. The collected clinical features encompassed sensory symptoms, motor weakness, gait abnormalities and deep tendon reflexes. Patients were classified based on clinical phenotypes, distinguishing between length-dependent and non-length dependent, sensory or sensory-motor involvement and their peripheral neuropathy disability (PND) score (ranging from I to IV). Neurophysiological data analysis followed the criteria of Hadden et al. to identify patients with demyelinating criteria, while those lacking demyelinating criteria were categorized as "axonal" in the neuropathy group. Simultaneously, biochemical evaluations of serum vitamin B12 and B9 by CLIA methods (Roche), along with plasma homocysteine by LC/MS/MS and CLIA methods (Snibe), methylmalonic acid (MMA), and methionine by LC/MS/MS, were systematically performed for all patients.Results40% of the selected patients exhibited demyelination criteria. The demyelinated group showed a significantly higher disability PND score compared to the axonal group (3.0 and 2.2, respectively; p-value = 0.028). Elevated levels of homocysteine and methylmalonic acid were found in all patients. Interestingly, plasma concentrations of homocysteine were significantly higher in the group of patient with axonal outcomes compared to the demyelinating group (90 μM and 114 μM; p-value = 0.04), suggesting an involvement of homocysteine in the type of lesion related to N 2 O abuse.ConclusionsThis study highlights the diverse electrophysiological manifestations of N 2 O-induced neuropathy and highlight the potential role of metabolic parameters as biomarkers to understand the pathophysiology. Indeed, lower hyperhomocysteinemia levels were observed in demyelinating patterns, highlighting a potentially biochemical difference between the groups: plasma homocysteine could also be used as a marker of neurological severity. The homocysteine assay used in these conditions must enable the patient to be managed rapidly: it would therefore be preferable to use rapid methods such as immunoanalysis. On the other hand, plasma methylmalonic acid did not differ between groups, which also suggests that other mechanisms have yet to be identified in the pathophysiology of N 2 O abuse.

The boon and bane of nitrous oxide

Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use

Nitrous oxide abuse direct measurement for diagnosis and follow-up: update on kinetics and impact on metabolic pathways

Using machine learning to identify factors related to nitrous oxide (laughing gas) relapse among adolescents.

Nitrous Oxide-Induced Neurotoxicity: Clinical Characteristics and Impacts on Overall Neurological Impairments.

Nitrous Oxide Use Precipitates Pulmonary Embolism: A Case Report

Mechanisms and recent advances in the diagnosis and treatment of nitrous oxide-induced peripheral neuropathy: a narrative review

Neuropsychiatric Symptoms Induced by Large Doses of Nitrous Oxide Inhalation: A Case Report

Clinical signs of nitrous oxide use: case report and review of the literature

FC33: Hilarious Gas for treatment resistant depression in older adults: is it really serious?

[Life style drug laughing gas (nitrous oxide, N2O) and the dependency criteria according to ICD-10]

B-301 Deciphering Neuropathy features in the Context of Nitrous Oxide abuse: An Integrated Analysis of Electrophysiology and Metabolism

Key Characteristics of Nitrous Oxide-Induced Neurological Disorders and Differences Between Populations

Does vitamin B12 deficiency explain psychiatric symptoms in recreational nitrous oxide users? A narrative review

Nitrous oxide abuse in a 21-year-old female: a case report and review of literature

More than just joy: A qualitative analysis of participant experiences during nitrous oxide sedation

Nitrous Oxide Alters Functional Connectivity in Medial Limbic Structures in Treatment-Resistant Major Depression

Nitrous Oxide Metabolism in Nitrate-Reducing Bacteria: Physiology and Regulatory Mechanisms

Acute Cognitive Disorder As the Initial Manifestation of Nitrous Oxide Abusing: a Case Report

Nitrous oxide abuse and associated neurological diseases